References: Receptors/Signaling

  1. Induction of proto-oncogene and cytokine expression in human peripheral blood monocytes and the monocytic cell line THP-1 after stimulation with mycoplasma-derived material MDHM.
    Quentmeier H, Schumann-Kindel G, Muhlradt PF, Drexler HG. Leuk Res. 1994 May;18(5):319-25.

  2. A Mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways.
    Garcia J, Lemercier B, Roman-Roman S, Rawadi G. J Biol Chem. 1998 Dec 18;273(51):34391-8.

  3. Activation of nuclear factor-kappaB in macrophages by mycoplasmal lipopeptides.
    Sacht G, Marten A, Deiters U, Sussmuth R, Jung G, Wingender E, Muhlradt PF. Eur J Immunol. 1998 Dec;28(12):4207-12.

  4. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.
    Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S. J Immunol. 2000 Jan 15;164(2):554-7.

  5. Discrimination of bacterial lipoproteins by Toll-like receptor 6.
    Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S. Int Immunol. 2001 Jul;13(7):933-40.

  6. CD36 is a sensor of diacylglycerides.
    Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, Beutler B. Nature. 2005 Feb 3;433(7025):523-7.2002 Dec;32(12):3337-47.

  7. TIR domain-containing adaptors define the specificity of TLR signaling.
    Yamamoto M, Takeda K, Akira S. Mol Immunol. 2004 Feb;40(12):861-8.

  8. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination.
    Omueti KO, Beyer JM, Johnson CM, Lyle EA, Tapping RI. J Biol Chem. 2005 Nov 4;280(44):36616-25.

  9. Toll-like receptor 6-independent signaling by diacylated lipopeptides.
    Buwitt-Beckmann U, Heine H, Wiesmüller KH, Jung G, Brock R, Akira S, Ulmer AJ. Eur J Immunol. 2005 Jan;35(1):282-9.

  10. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
    Yoshida H, Jono H, Kai H, Li JD. J Biol Chem. 2005 Dec 9;280(49):41111-21. Epub 2005 Oct 17.

  11. Microbial products stimulate human Toll-like receptor 2 expression through histone modification surrounding a proximal NF-kappaB-binding site.
    Johnson CM, Tapping RI. J Biol Chem. 2007 Oct 26;282(43):31197-205. Epub 2007 Aug 29.

  12. ATF-2 regulates lipopolysaccharide-induced transcription in macrophage cells.
    Hirose N, Maekawa T, Shinagawa T, Ishii S. Biochem Biophys Res Commun. 2009 Jul 17;385(1):72-7. Epub 2009 May 5.

  13. 14. Toll-like receptor ligands cause proinflammatory and prodiabetic activation of adipocytes via phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase but not interferon regulatory factor-3.
    Kopp A, Buechler C, Bala M, Neumeier M, Schölmerich J, Schäffler A. Endocrinology. 2010 Mar;151(3):1097-108. Epub 2010 Feb 3.

top of page

References are directly linked to the according page on the NCBI (National Center for Biotechnology Information) page.